Target Name: GUCY1B1
NCBI ID: G2983
Review Report on GUCY1B1 Target / Biomarker Content of Review Report on GUCY1B1 Target / Biomarker
GUCY1B1
Other Name(s): GUCY1B3 | Guanylate cyclase soluble subunit beta-1 | GC-S-beta-1 | guanylate cyclase 1 soluble subunit beta 1 | GCS-beta-1 | GUCSB3 | GUC1B3 | guanylate cyclase soluble subunit beta-3 | GCS-beta-3 | guanylate cyclase 1, soluble, beta 3 | GCYB1_HUMAN | Guanylate cyclase soluble subunit beta-1 (isoform 2) | GC-SB3 | soluble guanylate cyclase small subunit | GUCY1B1 variant 2 | GUCB3 | Soluble guanylate cyclase small subunit | Guanylate cyclase 1 soluble subunit beta 1, transcript variant 2 | Guanylate cyclase soluble subunit beta-3

Understanding GUCY1B1: A Potential Drug Target and Biomarker for Disease

GUCY1B1 (GUCY1B3) is a protein that is expressed in various tissues of the body, including the brain, pancreas, and muscle. Its function is not well understood, but it is known to play a role in the regulation of cellular processes such as cell adhesion, migration, and survival.

GUCY1B1 is a member of the Gucy family of proteins, which are characterized by the presence of a unique N-terminal domain called Gucy1. Gucy1 is a transmembrane protein that contains a unique structural domain called Gucy2, which is involved in the formation of a hydrophobic core. Gucy1B1 and Gucy1B3 are both N-terminal extensions of the Gucy1 protein that contain additional amino acids.

GUCY1B1 is expressed in a variety of tissues and organs, including the brain, pancreas, and muscle. It is highly expressed in the brain, where it is found in the endoplasmic reticulum (ER) and in the cytoplasm. Gucy1B1 is also expressed in the pancreas, where it is found in the intranubial ducts, and in the muscle, where it is found in the sarcolemma.

GUCY1B1 is involved in the regulation of cellular processes that are important for tissue repair and regeneration. It has been shown to play a role in the regulation of cell adhesion and migration, as well as in the regulation of cellular signaling pathways that are involved in cell survival.

One of the most promising aspects of GUCY1B1 is its potential as a drug target. Gucy1B1 has been shown to play a role in a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. Its expression is often reduced in these diseases, and its overexpression has been shown to contribute to the development and progression of these conditions.

GUCY1B1 is also a potential biomarker for these diseases. Its expression is often reduced in individuals with cancer, neurodegenerative diseases, and autoimmune diseases, and its levels can be increased in the diagnosis of these conditions. For example, Gucy1B1 has been shown to be reduced in individuals with Alzheimer's disease, and its levels have been increased in individuals with multiple sclerosis.

GUCY1B1 is a complex protein that is involved in the regulation of cellular processes that are important for tissue repair and regeneration. Its expression is often reduced in a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. Its overexpression has been shown to contribute to the development and progression of these conditions, and it is a potential drug target and biomarker for these diseases. Further research is needed to fully understand its role in these processes and its potential as a therapeutic target.

Protein Name: Guanylate Cyclase 1 Soluble Subunit Beta 1

Functions: Mediates responses to nitric oxide (NO) by catalyzing the biosynthesis of the signaling molecule cGMP

The "GUCY1B1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GUCY1B1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

GUCY1B2 | GUCY2C | GUCY2D | GUCY2EP | GUCY2F | GUCY2GP | GUF1 | GUK1 | GULOP | GULP1 | GUSB | GUSBP1 | GUSBP11 | GUSBP12 | GUSBP14 | GUSBP15 | GUSBP17 | GUSBP2 | GUSBP3 | GUSBP4 | GUSBP5 | GUSBP8 | GVINP1 | GVQW3 | GXYLT1 | GXYLT1P3 | GXYLT1P4 | GXYLT1P6 | GXYLT2 | GYG1 | GYG2 | GYPA | GYPB | GYPC | GYPE | GYS1 | GYS2 | GZF1 | GZMA | GZMB | GZMH | GZMK | GZMM | H1-0 | H1-1 | H1-10 | H1-10-AS1 | H1-2 | H1-3 | H1-4 | H1-5 | H1-6 | H1-7 | H1-8 | H1-9P | H19 | H19-ICR | H2AB1 | H2AB2 | H2AB3 | H2AC1 | H2AC11 | H2AC12 | H2AC13 | H2AC14 | H2AC15 | H2AC16 | H2AC17 | H2AC18 | H2AC20 | H2AC21 | H2AC25 | H2AC3P | H2AC4 | H2AC6 | H2AC7 | H2AJ | H2AP | H2AX | H2AZ1 | H2AZ1-DT | H2AZ2 | H2AZ2-DT | H2AZP2 | H2BC1 | H2BC10 | H2BC11 | H2BC12 | H2BC12L | H2BC13 | H2BC14 | H2BC15 | H2BC17 | H2BC18 | H2BC20P | H2BC21 | H2BC26 | H2BC27P | H2BC3 | H2BC4